Upload
aaron-horton
View
218
Download
1
Embed Size (px)
Citation preview
CONFIDENTIAL
This report is solely for the use of client personnel. No part of it may be circulated, quoted, or reproduced for distribution outside the client organization without prior written approval from The Mattson Jack Group, Inc.
Building Blocks (and the Devil) inCommercial Assessment and Planning
Richard W. Martin, President and Chief Operating Officer
The Mattson Jack Group, Inc.
April 2008
Confidential2
Introduction
Multiple slides
Confidential3
The Devils of Commercial Assessment and Planning
Epidemiology
Patient Behavior
Treatment Protocols
Regulatory Environment
Competitive Set
Logistics and Supply
Commercialization Strategy
Partner Coordination
Financial Considerations
Commercial Environment
Confidential4
Epidemiology is the starting point in the pharmaceutical commercial market assessment and planning process.
How many patients have the disease or condition and are eligible to be treated?
• Drug discovery prioritization
• Clinical trial planning
• Licensing
• Additional indications for in-line products
• Resource allocation and investment decisions
• Go / no-go decisions all along the way
Too often, too little attention is paid to this critical element of business planning.
• Epidemiology is the first potential major “trip up” in the commercial assessment and planning process
• The impact of errors here are multiplied throughout the planning process
Confidential5
Epidemiology non-oncology examples
Multiple slides
Confidential6
Changes in core disease rates can trip up the best planners.
The previous examples show the effect of demographics when the rate of disease is static. What happens when the disease rate also changes?
One must analyze the “age-adjusted” disease rate.
• An overall disease rate is dependent on demographic composition at the time the rate was determined.
• An age-adjusted rate corrects for changes in demographic composition.
Confidential7
Epidemiology oncology examples
Multiple slides
Confidential8
Co-Morbid Considerations
Why is it important to consider co-morbid diseases / conditions?
• To prevent “double counting” resulting in over- or under-estimating market size
• For example, many individual compounds are used to treat multiple psychiatric conditions
Where should one be most careful regarding co-morbid diseases / conditions? (And, let’s not forget about severity)
• Respiratory disease (asthma, COPD, allergic rhinitis)
• Multiple indications for a single product (e.g., Sanofi-Aventis’ rimonabant originally considered for smoking, obesity, hypertension and diabetes together)
• Psychiatric illnesses (depression, anxiety, others)
Confidential9
Co-morbidity examples
Multiple slides
Confidential10
Patient Behavior
Preferences
Embarrassed
What’s
“Normal?”
And so it goes
Confidential11
Treatment Protocol
Economics
How
Aggressive?
Managed Care
Confidential12
Commercial Environment
IP
Pricing and
Reimbursement
Me-toos and
Generics
Confidential13
Competitive Environment
What’s in
Development?
Regional
PlayersParallel
Importation
Confidential14
Regulatory Environment
Timeline,
Cost, P(s)
Acceptable
TPPsStudy
Requirements
Confidential15
Commercialization Strategies
Partnering
HQ vs. Local
Planning
Promotion
Confidential16
Partner Coordination
Pricing (again)
Unplanned
ExpensesPromotional
Bleed
Confidential17
Logistics and Supply
Local
Incentives
Importation
Costs“Special”
Payments
Confidential18
Financial Considerations
Taxation
Currency
Consolidation
Confidential19
Richard W. MartinPresident and COOThe Mattson Jack Group, Inc.11960 Westline Drive, Suite 180St. Louis, MO 63146Tel: 314.469-7600 Fax: 314.469.6794
E-mail: [email protected] www.mattsonjack.com
Thank You!